What the study found
The study found that catechol-O-methyltransferase inhibitors, or COMT inhibitors, used with levodopa for Parkinson's disease symptoms can act as antibiotics and alter gut microbiome-related levodopa metabolism. The effects depended on iron availability and varied across human fecal microbial communities.
Why the authors say this matters
The authors conclude that the gut microbiome may help mediate drug-drug interactions. The study suggests that microbial features could help predict individual responses to co-prescribed drugs.
What the researchers tested
The researchers examined the antibiotic properties of COMT inhibitor drugs in vitro, ex vivo, and in vivo. They also studied how these interactions changed microbiome-mediated levodopa metabolism in vitro and ex vivo, including tests in human fecal microbial communities.
What worked and what didn't
In vitro, extracellular iron could drive non-enzymatic inactivation of COMT inhibitors, which rescued COMT inhibitor-mediated bacterial iron starvation responses. At the same time, limiting intracellular iron could protect sensitive bacteria from COMT inhibitor antibiotic activity. When COMT inhibitors and levodopa were co-administered to human fecal microbial communities ex vivo, COMT inhibitor-dependent changes in levodopa metabolism were seen in an individual-specific manner.
What to keep in mind
The abstract does not give detailed effect sizes, sample sizes, or clinical outcome data. It also does not describe limitations beyond the scope of the experiments summarized here.
Key points
- COMT inhibitors used with levodopa can alter gut microbiome composition.
- Iron availability changes COMT inhibitor antibiotic activity in vitro.
- Extracellular iron can inactivate COMT inhibitors non-enzymatically.
- Intracellular iron limitation can protect sensitive bacteria from COMT inhibitor activity.
- Co-administration with levodopa changed microbial levodopa metabolism in an individual-specific way ex vivo.
Disclosure
- Research title:
- COMT inhibitors alter microbiome-linked L-DOPA metabolism
- Authors:
- Andrew A Verdegaal, Joonseok Oh, Bahar Javdan, Ruojun Wang, Qihao Wu, Timothy R. W. Wang, Jaime A. González-Hernández, Mohamed S. Donia, Jason M. Crawford, Andrew L. Goodman
- Institutions:
- Amgen (United States), Medpace (United States), Princeton University, Princeton University, Princeton University, University of Pittsburgh, Yale University, Yale University, Yale University, Yale University, Yale University, Yale University, Yale University, Yale University
- Publication date:
- 2026-04-06
- OpenAlex record:
- View
Get the weekly research newsletter
Stay current with scholarly research without reading academic papers — one filtered digest, every Friday.